The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Elisabetta Fratta, Sandra Coral, Alessia Covre, Giulia Parisi, Francesca Colizzi, Riccardo Danielli, Hugues Jean Marie Nicolay, Luca Sigalotti, Michele Maio

Research output: Contribution to journalArticle

Abstract

Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues except for testis and placenta. This tumor-restricted pattern of expression, together with their strong in vivo immunogenicity, identified CTA as ideal targets for tumor-specific immunotherapeutic approaches, and prompted the development of several clinical trials of CTA-based vaccine therapy. Driven by this practical clinical interest, a more detailed characterization of CTA biology has been recently undertaken. So far, at least 70 families of CTA, globally accounting for about 140 members, have been identified. Most of these CTA are expressed during spermatogenesis, but their function is still largely unknown. Epigenetic events, particularly DNA methylation, appear to be the primary mechanism regulating CTA expression in both normal and transformed cells, as well as in cancer stem cells. In view of the growing interest in CTA biology, the aim of this review is to provide the most recent information on their expression, regulation and function, together with a brief summary of the major clinical trials involving CTA as therapeutic agents. The pharmacologic modulation of CTA expression profiles on neoplastic cells by DNA hypomethylating drugs will also be discussed as a feasible approach to design new combination therapies potentially able to improve the clinical efficacy of currently adopted CTA-based immunotherapeutic regimens in cancer patients.

Original languageEnglish
Pages (from-to)164-182
Number of pages19
JournalMolecular Oncology
Volume5
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Testicular Neoplasms
Antigens
Therapeutics
Neoplasms
Clinical Trials
Active Immunotherapy
Neoplastic Stem Cells
Neoplasm Antigens
DNA Methylation
Spermatogenesis
Epigenomics
Placenta
Testis

Keywords

  • 5-AZA-2′-deoxycytidine
  • Cancer testis antigens
  • DNA methylation
  • Immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., ... Maio, M. (2011). The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Molecular Oncology, 5(2), 164-182. https://doi.org/10.1016/j.molonc.2011.02.001

The biology of cancer testis antigens : Putative function, regulation and therapeutic potential. / Fratta, Elisabetta; Coral, Sandra; Covre, Alessia; Parisi, Giulia; Colizzi, Francesca; Danielli, Riccardo; Marie Nicolay, Hugues Jean; Sigalotti, Luca; Maio, Michele.

In: Molecular Oncology, Vol. 5, No. 2, 04.2011, p. 164-182.

Research output: Contribution to journalArticle

Fratta, E, Coral, S, Covre, A, Parisi, G, Colizzi, F, Danielli, R, Marie Nicolay, HJ, Sigalotti, L & Maio, M 2011, 'The biology of cancer testis antigens: Putative function, regulation and therapeutic potential', Molecular Oncology, vol. 5, no. 2, pp. 164-182. https://doi.org/10.1016/j.molonc.2011.02.001
Fratta, Elisabetta ; Coral, Sandra ; Covre, Alessia ; Parisi, Giulia ; Colizzi, Francesca ; Danielli, Riccardo ; Marie Nicolay, Hugues Jean ; Sigalotti, Luca ; Maio, Michele. / The biology of cancer testis antigens : Putative function, regulation and therapeutic potential. In: Molecular Oncology. 2011 ; Vol. 5, No. 2. pp. 164-182.
@article{b705133304824996816f28f7e55344c3,
title = "The biology of cancer testis antigens: Putative function, regulation and therapeutic potential",
abstract = "Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues except for testis and placenta. This tumor-restricted pattern of expression, together with their strong in vivo immunogenicity, identified CTA as ideal targets for tumor-specific immunotherapeutic approaches, and prompted the development of several clinical trials of CTA-based vaccine therapy. Driven by this practical clinical interest, a more detailed characterization of CTA biology has been recently undertaken. So far, at least 70 families of CTA, globally accounting for about 140 members, have been identified. Most of these CTA are expressed during spermatogenesis, but their function is still largely unknown. Epigenetic events, particularly DNA methylation, appear to be the primary mechanism regulating CTA expression in both normal and transformed cells, as well as in cancer stem cells. In view of the growing interest in CTA biology, the aim of this review is to provide the most recent information on their expression, regulation and function, together with a brief summary of the major clinical trials involving CTA as therapeutic agents. The pharmacologic modulation of CTA expression profiles on neoplastic cells by DNA hypomethylating drugs will also be discussed as a feasible approach to design new combination therapies potentially able to improve the clinical efficacy of currently adopted CTA-based immunotherapeutic regimens in cancer patients.",
keywords = "5-AZA-2′-deoxycytidine, Cancer testis antigens, DNA methylation, Immunotherapy",
author = "Elisabetta Fratta and Sandra Coral and Alessia Covre and Giulia Parisi and Francesca Colizzi and Riccardo Danielli and {Marie Nicolay}, {Hugues Jean} and Luca Sigalotti and Michele Maio",
year = "2011",
month = "4",
doi = "10.1016/j.molonc.2011.02.001",
language = "English",
volume = "5",
pages = "164--182",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The biology of cancer testis antigens

T2 - Putative function, regulation and therapeutic potential

AU - Fratta, Elisabetta

AU - Coral, Sandra

AU - Covre, Alessia

AU - Parisi, Giulia

AU - Colizzi, Francesca

AU - Danielli, Riccardo

AU - Marie Nicolay, Hugues Jean

AU - Sigalotti, Luca

AU - Maio, Michele

PY - 2011/4

Y1 - 2011/4

N2 - Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues except for testis and placenta. This tumor-restricted pattern of expression, together with their strong in vivo immunogenicity, identified CTA as ideal targets for tumor-specific immunotherapeutic approaches, and prompted the development of several clinical trials of CTA-based vaccine therapy. Driven by this practical clinical interest, a more detailed characterization of CTA biology has been recently undertaken. So far, at least 70 families of CTA, globally accounting for about 140 members, have been identified. Most of these CTA are expressed during spermatogenesis, but their function is still largely unknown. Epigenetic events, particularly DNA methylation, appear to be the primary mechanism regulating CTA expression in both normal and transformed cells, as well as in cancer stem cells. In view of the growing interest in CTA biology, the aim of this review is to provide the most recent information on their expression, regulation and function, together with a brief summary of the major clinical trials involving CTA as therapeutic agents. The pharmacologic modulation of CTA expression profiles on neoplastic cells by DNA hypomethylating drugs will also be discussed as a feasible approach to design new combination therapies potentially able to improve the clinical efficacy of currently adopted CTA-based immunotherapeutic regimens in cancer patients.

AB - Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues except for testis and placenta. This tumor-restricted pattern of expression, together with their strong in vivo immunogenicity, identified CTA as ideal targets for tumor-specific immunotherapeutic approaches, and prompted the development of several clinical trials of CTA-based vaccine therapy. Driven by this practical clinical interest, a more detailed characterization of CTA biology has been recently undertaken. So far, at least 70 families of CTA, globally accounting for about 140 members, have been identified. Most of these CTA are expressed during spermatogenesis, but their function is still largely unknown. Epigenetic events, particularly DNA methylation, appear to be the primary mechanism regulating CTA expression in both normal and transformed cells, as well as in cancer stem cells. In view of the growing interest in CTA biology, the aim of this review is to provide the most recent information on their expression, regulation and function, together with a brief summary of the major clinical trials involving CTA as therapeutic agents. The pharmacologic modulation of CTA expression profiles on neoplastic cells by DNA hypomethylating drugs will also be discussed as a feasible approach to design new combination therapies potentially able to improve the clinical efficacy of currently adopted CTA-based immunotherapeutic regimens in cancer patients.

KW - 5-AZA-2′-deoxycytidine

KW - Cancer testis antigens

KW - DNA methylation

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=79955475321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955475321&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2011.02.001

DO - 10.1016/j.molonc.2011.02.001

M3 - Article

C2 - 21376678

AN - SCOPUS:79955475321

VL - 5

SP - 164

EP - 182

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -